Airody, Archana
Baseler, Heidi A.
Seymour, Julie
Allgar, Victoria
Mukherjee, Rajarshi
Downey, Louise
Dhar-Munshi, Sushma
Mahmood, Sajjad
Balaskas, Konstantinos
Empeslidis, Theo
Hanson, Rachel L. W.
Dorey, Tracey
Szczerbicki, Tom
Sivaprasad, Sobha
Gale, Richard P.
Funding for this research was provided by:
Bayer, United Kingdom
Article History
Received: 15 July 2022
Accepted: 30 March 2023
First Online: 20 April 2023
Declarations
:
: AA is partly funded through Bayer. LD has received consultancy fees from Bayer, Novartis, Roche, Alimera, Allergan, Bausch and Lomb and travel grants from Bayer, Novartis, Roche and Allergan. RM has received consultancy and speaker fees from Novartis, Bayer, Alimera and Allergan/AbbVie. SM has received consultancy fees, lecturing fees and travel grants from Bayer and Novartis. SS has received honorarium for advisory board meetings and speaker fees from Allergan, Boehringer Ingelheim, Novartis, Bayer, Optos, Heidelberg Engineering, Oxurion, Opthea, Oculis, Apellis and Roche; been awarded institutional research grants by Novartis, Bayer, Allergan and Boehringer Ingelheim; and received support from industry towards publication for the AURA and RELIGHT and research grants from Novartis, Bayer, Allergan, Boehringer Ingelheim, Optos and Opthea. RPG is a grant holder who received honorarium from Novartis and Bayer. The other authors declare that they have no competing interests.